MASTL Conjugated Antibody

Catalog No: #C35289

Package Size: #C35289-AF350 100ul #C35289-AF405 100ul #C35289-AF488 100ul #C35289-AF555 100ul #C35289-AF594 100ul #C35289-AF647 100ul #C35289-AF680 100ul #C35289-AF750 100ul #C35289-Biotin 100ul

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	MASTL Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu
Specificity	The antibody detects endogenous levels of total MASTL protein.
Immunogen Description	Synthesized peptide derived from C-terminal of human MASTL.
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	FLJ14813;MASTL;microtubule associated serine/threonine kinase-like;Microtubule-associated serine/threonine-protein kinase-like;RP11-85G18.2
Accession No.	Swiss-Prot#:Q96GX5NCBI Gene ID:84930
Uniprot	Q96GX5
GeneID	84930;
Excitation Emission	AF350: 346nm/442nm AF405: 401nm/421nm AF488: 493nm/519nm AF555: 555nm/565nm AF594: 591nm/614nm AF647: 651nm/667nm AF680: 679nm/702nm AF750: 749nm/775nm
Calculated MW	97
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250

AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250

AF555 conjugated: most applications: 1: 50 - 1: 250

AF594 conjugated: most applications: 1: 50 - 1: 250

AF647 conjugated: most applications: 1: 50 - 1: 250

AF680 conjugated: most applications: 1: 50 - 1: 250

AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Product Description

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Background

Serine/threonine kinase that plays a key role in M phase by acting as a regulator of mitosis entry and maintenance. Acts by promoting the inactivation of protein phosphatase 2A (PP2A) during M phase: does not directly inhibit PP2A but acts by mediating phosphorylation and subsequent activation of ARPP19 and ENSA at 'Ser-62' and 'Ser-67', respectively. ARPP19 and ENSA are phosphatase inhibitors that specifically inhibit the PPP2R2D (PR55-delta) subunit of PP2A. Inactivation of PP2A during M phase is essential to keep cyclin-B1-CDK1 activity high. Following DNA damage, it is also involved in checkpoint recovery by being inhibited. Phosphorylates histone protein in vitro; however such activity is unsure in vivo. May be involved in megakaryocyte differentiation.

Note: This product is for in vitro research use only